NASDAQ:RNA - Avidity Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $43.33
  • Forecasted Upside: 106.64 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$20.97
▲ +0.85 (4.22%)
Get New Avidity Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RNA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$43.33
▲ +106.64% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Avidity Biosciences in the last 3 months. The average price target is $43.33, with a high forecast of $60.00 and a low forecast of $34.00. The average price target represents a 106.64% upside from the last price of $20.97.
Buy
The current consensus among 4 investment analysts is to buy stock in Avidity Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/7/2020SVB LeerinkInitiated CoverageOutperform$36.00N/A
i
Rating by J. Schwartz at SVB Leerink LLC
7/7/2020CowenInitiated CoverageOutperformN/A
i
7/7/2020Wells Fargo & CompanyInitiated CoverageOverweight$60.00N/A
i
7/7/2020Credit Suisse GroupInitiated CoverageOutperform$34.00N/A
i
(Data available from 4/22/2016 forward)
Avidity Biosciences logo
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.
Read More

Today's Range

Now: $20.97
$19.74
$21.05

50 Day Range

MA: N/A

52 Week Range

Now: $20.97
$4.12
$22.80

Volume

211,984 shs

Average Volume

260,559 shs

Market Capitalization

$787.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Avidity Biosciences?

The following Wall Street sell-side analysts have issued stock ratings on Avidity Biosciences in the last year: Cowen Inc, Credit Suisse Group AG, SVB Leerink LLC, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for RNA.

What is the current price target for Avidity Biosciences?

3 Wall Street analysts have set twelve-month price targets for Avidity Biosciences in the last year. Their average twelve-month price target is $43.33, suggesting a possible upside of 106.6%. Wells Fargo & Company has the highest price target set, predicting RNA will reach $60.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $34.00 for Avidity Biosciences in the next year.
View the latest price targets for RNA.

What is the current consensus analyst rating for Avidity Biosciences?

Avidity Biosciences currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RNA will outperform the market and that investors should add to their positions of Avidity Biosciences.
View the latest ratings for RNA.

What other companies compete with Avidity Biosciences?

How do I contact Avidity Biosciences' investor relations team?

Avidity Biosciences' physical mailing address is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. The biotechnology company's listed phone number is 858-401-7900 and its investor relations email address is [email protected] The official website for Avidity Biosciences is www.aviditybiosciences.com.